Advertisement

Topics

Genmab Inc. Company Profile

10:49 EST 15th December 2018 | BioPortfolio

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.’s array of proprietary technologies, including the UltiMAb® platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is an international company with operations in Europe and the United States.

Location

457 North Harrison Street
Princeton
New Jersey
08540
United States of America

Contact

Phone: 1 609 430-2481
Fax: 1 609 430-2482
Email: info@genmab.com


News Articles [60 Associated News Articles listed on BioPortfolio]

Genmab Partners with Immatics for Development of Next Generation Bispecific Cancer Immunotherapies

Copenhagen, Denmark; July 12, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has entered into a research collaboration and exclusive license agreement with privately owned Immat...

Genmab and Immatics to develop bispecific cancer therapies

Danish biotechnology company Genmab has formed a collaboration and exclusive licence alliance with Germany-based Immatics Biotechnologies. The alliance will focus...Read More... The post Genmab and Im...

Genmab and Immatics Partner on Next-Generation T-Cell Bispecific Immunotherapies Program

Denmark-based Genmab A/S struck a discovery and development deal with Immatics Biotechnologies GmbH.

Genmab, Immatics Launch Up-to-$2.8B+ Cancer Immunotherapy Partnership

Genmab will partner with Immatics Biotechnologies to discover and develop next-generation bispecific cancer immunotherapies through a collaboration that could generate more than $2.8 billion for Immat...

Genmab partners with Immatics on cancer immunotherapy R&D

Genmab and Immatics Biotechnologies agreed to collaborate on next-generation bispecific cancer immunotherapies research and d -More- 

Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal

Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it...   

Janssen's Daratumumab SNDA In Japan Triggers $2 Mln Milestone Payment To Genmab

NEW BRUNSWICK (dpa-AFX) - Danish biotechnology company Genmab A/S announced Thursday that Janssen Pharmaceutical K.K. has submitted a supplemental new drug application or sNDA in Japan for Daratum...

Genmab Positive Topline Results in P3 CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma $GEN $JNJ https://ir.genmab.com/news-releases/news-release-details/genmab-announces-positive-topline-results-phase-iii-cassiopeia/ …

Genmab Positive Topline Results in P3 CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma $GEN $JNJ https://ir.genmab.com/news-releases/news-release-details/genmab-announces-positive-top...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [5 Associated Companies listed on BioPortfolio]

Genmab Inc.

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat c...

Genmab A/S

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Den...

TenX Biopharma, Inc.

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights ...

BioNTech AG

BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combin...

BioNTech and Genevant Sciences

BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combin...

More Information about "Genmab Inc." on BioPortfolio

We have published hundreds of Genmab Inc. news stories on BioPortfolio along with dozens of Genmab Inc. Clinical Trials and PubMed Articles about Genmab Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genmab Inc. Companies in our database. You can also find out about relevant Genmab Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record